XML 71 R53.htm IDEA: XBRL DOCUMENT v3.23.1
Collaboration and License Agreements - ModernaTX, Inc - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Jan. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2022
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Deferred revenue             $ 301,326 $ 284,760 $ 318,707
Revenue recognized   $ 11,147 $ 12,853 $ 9,040 $ 21,893 $ 33,040 53,163 $ 37,312  
ModernaTX, Inc                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Deferred revenue             35,000    
ModernaTX, Inc | Collaboration and License Agreement                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Total transaction price             51,700    
Upfront Fee Received             30,000    
Estimated research fund             21,700    
Deferred revenue             35,000    
Revenue recognized             $ 0    
Estimated research service period             4 years    
ModernaTX, Inc | Collaboration and License Agreement | Subsequent Event                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Upfront payment received $ 35,000                
Upfront consideration, pre-paid research funding 5,000                
ModernaTX, Inc | Collaboration and License Agreement | Maximum | Subsequent Event                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Contingent milestone payments receivable $ 1,200,000